ifosfamide + etoposide + vinorelbine

ifosfamide + etoposide + vinorelbine, commonly referred to by the acronym **IVE**, is a potent combination chemotherapy salvage regimen primarily utilized in the treatment of relapsed or refractory pediatric and adult malignancies. The regimen combines three cytotoxic agents with non-overlapping toxicities and distinct mechanisms of action. **Ifosfamide** is an alkylating agent that cross-links DNA; **etoposide** is a semi-synthetic podophyllotoxin derivative that inhibits topoisomerase II, leading to double-strand DNA breaks; and **vinorelbine** is a semi-synthetic vinca alkaloid that inhibits microtubule polymerization, arresting the cell cycle in mitosis. This combination is particularly notable for its efficacy in high-risk neuroblastoma, relapsed Hodgkin lymphoma, and various soft tissue sarcomas, often serving as a bridge to hematopoietic stem cell transplantation.

Other names

IVEIVE regimenIVE protocolifosfamide/etoposide/vinorelbine